DaylightGov

H.R. 10857 · 119th Congress · Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

To amend the Federal Food, Drug, and Cosmetic Act and Public Health Service Act to advance the next-generation of clinical development of novel treatments and cures, and for other purposes.

We have not deep-analyzed this bill yet.

Here is what Congress.gov shows.

Sponsor
Rep. Auchincloss, Jake [D-MA-4] (D-MA), House
Cosponsors
1 cosponsor
  • Rep. Griffith, H. Morgan [R-VA-9] (R-VA)
Introduced
October 22, 2026
Latest action
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. (October 22, 2026)
Scanned
October 24, 2026
Read the bill text on Congress.gov

Public record

Below is the official voting record from Congress.gov. It is not our analysis.

Source: Congress.gov

This bill has no recorded roll-call vote yet. A roll-call vote records how each member voted by name.